K.J. Harrison & Partners’s Teva Pharmaceuticals TEVA Stock Holding History

K.J. Harrison & Partners’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-20,700	Closed	-$688K	–	189
2017 Q2	$688K	Hold	20,700	–	–	0.27%	108
2017 Q1	$664K	Hold	20,700	–	–	0.27%	95
2016 Q4	$750K	Hold	20,700	–	–	0.3%	97
2016 Q3	$952K	Hold	20,700	–	–	0.45%	74
2016 Q2	$1.04M	Hold	20,700	–	–	0.56%	66
2016 Q1	$1.11M	Hold	20,700	–	–	0.59%	59
2015 Q4	$1.36M	Hold	20,700	–	–	0.6%	60
2015 Q3	$1.17M	Sell	20,700 -200	-1%	-$13K	0.57%	62
2015 Q2	$1.24M	Hold	20,900	–	–	0.37%	80
2015 Q1	$1.3M	Hold	20,900	–	–	0.38%	80
2014 Q4	$1.2M	Hold	20,900	–	–	0.35%	75
2014 Q3	$1.12M	Hold	20,900	–	–	0.31%	82
2014 Q2	$1.1M	Hold	20,900	–	–	0.31%	83
2014 Q1	$1.1M	Hold	20,900	–	–	0.33%	81
2013 Q4	$891K	Hold	20,900	–	–	0.26%	87
2013 Q3	$790K	Hold	20,900	–	–	0.29%	80
2013 Q2	$819K	Buy	+20,900	New	+$814K	0.33%	79

Other funds holding TEVA

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

K.J. Harrison & Partners's TEVA Position: Q3 2017 in Review

K.J. Harrison & Partners sold out of Teva Pharmaceuticals (TEVA) in Q3 2017, closing a stake of 20,700 shares — an estimated $688K sold.

K.J. Harrison & Partners first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $1.36M in Q4 2015. 535 funds tracked by Wall St. Rank hold TEVA as of Q3 2017.

K.J. Harrison & Partners reported no remaining Teva Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
K.J. Harrison & Partners sold 20,700 Teva Pharmaceuticals shares in Q3 2017, an estimated $688K.
K.J. Harrison & Partners first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
K.J. Harrison & Partners's Teva Pharmaceuticals position peaked at $1.36M in Q4 2015.
535 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2017.

Based on K.J. Harrison & Partners's 13F filing for Q3 2017, filed 27 Oct 2017.